



YOUR RELIABLE BIOLOGICS PARTNER

Capital Securities - 3Q2022 Investment Forum Sept 13, 2022

Lee-Cheng (LC) Liu, Ph. D. Founder, Chairman & President

DISCLAIMER



This material has been prepared by EirGenix, Inc. ("EirGenix").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. EirGenix is under no obligation to update or keep current the information contained herein. The information contained in this presentation is EirGenix's confidential information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of EirGenix. Without limiting the foregoing, statements including the words "believes", "anticipates", "plans", "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management's plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.

No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to, the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.



EirGenix Profile and USPs

- Established Dec. 21, 2012
 - 2013/03 Completed acquisition of DCB's Biopharmaceutical Pilot Facility Lovelopment Center for Development Cent
 - 2019/06 IPO on TPEx (Code: 6589.TWO) China Area Award
- Back up by very strong and stable investors include:
 - Founder of Foxconn, Terry Gou
 - Government and pan-government investment funds
 - Formosa Laboratories
- Dual business model: CDMO Services and Own-Product Development (Biosimilars)
- CDMO Achievements
 - 2018 Asia's Best Biologics CMO Award
 - 2019 BioProcessing Excellence in Taiwan Award
 - 2020 BioProcessing Excellence in Greater China Area Award
- Rated 2021 Top 5% Corporate Governance Evaluation at TPEx after second year of the IPO



EirGenix Office, Facilities & Business Partners




Recent Zhubei Facility Expansion Update

Zhubei - Building B (Microbial Production Line) Currently under construction, expect to be ready by 2024-end for

1x 350L and,

1x 1000L production lines

Zhubei- Building A (Mammalian Production Line)
Started production since 2019



5F: New production line to ready by 2023 Q1 for 3 sets 2x 2000L

3F: 3Q2022 Expansion completed. Latest 3F production line has 3 sets 2x 2000L capacity



Capacity and Expansion Schedule (xizhi | Zhubei | STSP)

Mammalian Cell Culture Capacity 13,500 L (2023Q1to reach 25,500 L)






- 2019/Q1 The first large scale mammalian commercial production in the Zhubei facility on stream (3F)
- 2022/Q3 Additional 1 sets of 2x2000L mammalian capacity expansion completed. Totaled 13,500 L
- 2023/Q1 The 2nd mammalian cell culture production line to complete (3 sets of 2x2000L). Totaled 25,500 L
- Southern Taiwan Science Park (STSP) 150 KL very large-scale mammalian cell culture facility. Over three stages , 50 KL each at 2025/26, 2028, and 2030. Total mammalian capacity to reach 175.5 KL by 2030.

Microbial fermentation capacity – 150 L

(2024-end to reach **1,500L**)



 2024 Expansion of Zhubei facility Building "B" for microbial fermentation capacity (350 + 1000 L) with 2-3 downstream purification suites; Total microbial fermentation capacity to reach 1,500 L by 2024



Future Capacity Planning (Xizhi | Zhubei | STSP)

Southern Taiwan Science Park (STSP)

150 KL Mammalian Cell Culture Capacity (15,000L x 10)

Self-Products

Mainly for selfproduct, Biosimilar drug commercial projects

(include EG12014, EG1206A and other self-product market launch after 2026)

CDMO ClientCommercial Projects

Zhubei Facility 24,000L Mammalian Cell Culture Capacity (2,000L x 12)

1,350L Microbial fermentation capacity (350L + 1000L)

Self-Products

Biosimilar drug clinical and commercial projects

CDMO Client

PH1 | PH2 | PH3 |
Commercial Projects

<u>Xizhi Facility</u> 1,500L Mammalian Cell Culture Capacity (50L, 200L, 1000L) 150L Microbial fermentation capacity (30L, 150L)

CDMO Client

Mammalian - R&D | Pre-Clinical | PH1 | PH2 Projects (ready EUA application)

Microbial - Clinical Projects & Commercial Production Projects



Business Overview



CDMO Business Unit Manufacturing Platform

Mammalian Cell Line Platform

E. Coli Cell Line Platform

Protein Characterization Platform


Product Dev. Unit


Biosimilar Drugs Special Biological Products Novel Biologics/Biobetters



Revenue Momentum


◆ 2022 Jan-Aug CDMO newly signed contracts reaching 84.5% of 2021 full-year contracts






CDMO Projects & Stages (2020-2021)

- Mammalian & Microbial Dual Expression Systems
- Over 70 CDMO projects (2020-2021)
- 4 late-stage projects with near-term value
- Accelerated CDMO business momentum driven by cumulated experience



Revenue Momentum (from EG12014 Licensing fee)

Total licensing fee US\$70mn (Upfront Payment US\$5mn + Milestone US\$65mn)



Global Compliance & Certifications

- EirGenix strongly believes in adherence to global standards and continually seeks to meet these standards year after year



YEAR	PREVIOUS CERTIFICATION OR INSPECTION
2005	Mammalian Cell culture production facility granted GMP certificate by TFDA
2013	Microbial production facility granted GMP certificate by TFDA
2014	Mammalian cell culture and microbial production facilities were certificated by TFDA as a PIC/S GMP facility
2017	Granted Accreditation Certificate of Foreign Manufacturer by Minister of Health, Labor and Welfare, Japan
2020	Granted approval by Pharmaceuticals and Medical Devices Agency (PMDA), Japan
2020	Zhubei facility passed the inspection by Taiwan FDA
2022	Inspected by US FDA pending for inspection result
2022-end/2023	Expected inspection by EU EMA



Own Product Pipeline

Draiget Name	Drug Class	Indication	Target	PROGRESS				
Project Name				Pre-Clinical	Phase I	Phase II/III	MAA/BLA	Partner
EG12014 / EGI014 Trastuzumab Biosimilar	Monoclonal Antibody	Cancer	HER2					PARTNERED WITH SANDOZ A Novartis Division
EG1206A Pertuzumab Biosimilar	Monoclonal Antibody	Cancer	HER2					CURRENTLY CONFIDENTIAL
EG13074 TRZ (SC formulation)	Monoclonal Antibody	Cancer	HER2					CURRENTLY CONFIDENTIAL
EG12043 (TSY0110) Antibody Drug Conjugate	Antibody Drug Conjugate	Cancer	HER2					PARTNERED WITH FORMUSA LABORATORIES, INC.
EG13084 TRZ+PTZ (SC formulation)	Monoclonal Antibody	Cancer	HER2					
EG74032 CRM197 Carrier Protein	Carrier Protein for Vaccine Conjugates	N/A	Infectious /cancer					
EG62054 Biosimilar	Fusion Protein	Ophthalmology / Cancer	VEGF					

Self-Own Product Development Progress

Broad & diversified product pipeline; unique strategy of Her2 products franchise management

- The 1st own product, Herceptin Biosimilar EG12014 (Herwenda® Sandoz | Eirguson® EirGenix)
 - 2019/04 Signed global licensing (excluding Taiwan, Mainland China, Japan, S. Korea and Russia)
 agreement with Sandoz AG (of the Novartis Group) for the upfront and milestone payment of
 US\$ 70 millions plus the profit sharing of the future sales
 - 2021/03 Global Phase III Clinical Trial met no clinically and meaningful differences standard
 - 2021/12 Submitted both BLA in US and MAA in EU almost at the same time
 - 2022/6 US FDA finished Zhubei facility inspection, pending for inspection results (Due to Covid-19 condition, EMA may follow FDA's results based on the mutual recognition agreement)
 - Expect to receive marketing licensing approval by 2022-end/early-2023
- The 2nd own product Pertuzumab Biosimilar EG1206A
 - 2022/Q1 Submitted Phase 1 clinical (German PEI & EC)
 - 2022/05 Received approval for Phase I PK bio-similarity clinical study from German National Competent Authority and corresponding Ethic Committee.
 - 2022/08 80% healthy subjects enrolled for PH1 clinical trial




Why Her2 Family Products?

- The global market size of Immuno-Oncology products in 2021 is around \$63 billions USD, and is expected to reach \$93 billions USD at a CAGR of 10% in 2025
- The global market size of Her 2 positive breast cancer is around \$13 billions USD
- Using the combination of trastuzumab + pertuzumab to treat Her 2 positive metastatic breast cancer (MBC) is a standard procedure, and it also becomes a trend to use the combination therapy for treating early breast cancer (EBC)
- To develop EirGenix's own pertuzumab (EG1206A) and be the top 2 to launch the product would have the complimentary effect to enhance the market penetration of EirGenix's trastuzumab (EG12014)
- EG has developed the proprietary high concentration SC formulations for trastuzumab. High concentration SC formulation of EG12014 + EG1206A is being developed. The successful development of high concentration SC formulation will further enhance EG's Her 2 family products penetration in the market, and it will help EG dominate the Her 2 biosimilar market

EirGenix's EG1206A is the Biosimilar drug of Roche's Perjeta


- Perjeta is Roche's another Her2+ monoclonal antibody drug for treating breast cancer
- Perjeta's 2021 sales revenue reached CHF 3.96bn (~US\$ 4.2bn) and yet reaching sales peak
- Presuming biosimilar market value equivalent to 50% of the reference drug market value, which roughly ~US\$2.1bn (based on Perjeta 2021 sales)
- Based on above assumptions, every 10% market penetration expect to contribution US\$210mn sales revenue
- With additional combination therapy treatment using EG12014, likely to fuel sales momentum for EirGenix's EG12014



Reference Drug and Biosimilar Drug Market Share Change After Patent Expired

- Roche's Herceptin® North American market as an example. Other substitute drug and biosimilar drugs penetrated over 75% of its market share within three years, after its patent expired since 2019.
- Early entry biosimilar drug received marketing license in US (or EU) + Strong global distribution channels to have the advantage of wining larger market share after reference drug patent expired.

Biosimilar Herceptin monthly sales share



(註) Enhertu is co-owned by AstraZeneca and Daiichi Sankyo in treating HER2 positive breast cancer's antibody-drug conjugate (ADC)

Future Product Pipeline Overview

Biosimilars

New Formulations & Drug Delivery for Biosimilars

EG12014
EG1206A
EG12043

(TSY0110)

EG62054

EGXXXXX

EGXXXXX

EGXXXXX

EGXXXXX



New List to be:

- 1) In-house developed, or
- 2) In-licensed, or
- 3) Potential IO biosimilars development alliance

** Drug development alliance to reduce the high development cost & risks, also shorten market launch time.

Specialty Biologics

EG74032 | CRM 197

EG74091 HRV3C

Me-too/Novel (NCE)

BDC-1001

* Immune Stimulating Antibody Conjugate (ISAC) - collaboration

EirGenix expect to have market launch for a new drug product each year after 2026, hence the large-scale commercial production capability (Southern TW Science Park site) becomes very critical.



EirGenix's Future Roadmap


Cell & Gene Therapy CDMO

Biologic testing (CRO)

characterization &



Special cell based



Protein & antibody engineering (CRO)




Biopharmaceutical

CDMO

Biologic drug substance process development & manufacturing




Allogenic cell processing system



Autologus cell processing system



Gene delivery system manufacturing





Viral safety testing



- Mammalian Cell capacity to reach 175,500 L by 2030
- Microbial Cell capacity to reach 1,500 L by 2024
- Invest or M&A regional small-mid size CDMO, enrich global client profile
- Target to launch 6-8 biosimilar products by 2030 through:
 - In-House Developed
 - In-Licensing
 - Immuno-Oncology Biosimilar Development Alliance



Drug product delivery devices



Aseptic filling & Lyophilization Alliance with Formosa Lab. & M&A



Q & A

The health of the humankind and Client's Success is Our Priority



